BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring (NASDAQ:BYSI) will present a poster at the 2026 ASCO Annual Meeting in Chicago.

Rhea-AI Summary

BeyondSpring (NASDAQ:BYSI) will present a poster at the 2026 ASCO Annual Meeting in Chicago. The poster covers Study 303, a Phase 2 trial of plinabulin, docetaxel and pembrolizumab in metastatic NSCLC after acquired resistance to anti-PD-1/L1 therapies.

The presentation is scheduled for Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place, in the Lung Cancer – Non-Small Cell Metastatic session (Abstract 8567, Poster Board 357).

Argus May 18 session

+2.57% close to close Open Argus

Details

News Market Reaction – BYSI

In the May 18 session, BYSI gained 2.57%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an upcoming ASCO 2026 poster detailing a Phase 2 study of plinabulin/do...

Analysis

This announcement highlights an upcoming ASCO 2026 poster detailing a Phase 2 study of plinabulin/docetaxel plus pembrolizumab in 2L/3L metastatic NSCLC after resistance to PD-1/PD-L1 therapy. It continues BeyondSpring’s pattern of featuring plinabulin combinations at major oncology meetings. Investors may watch for efficacy and immunophenotyping data from Study 303 alongside prior AACR findings and recent financial disclosures to assess how the program evolves within the broader pipeline.

Key Figures

Treatment line: 2L/3L NSCLC Trial phase: Phase 2 ASCO 2026 dates: May 29–June 2, 2026 +4 more

Treatment line

2L/3L NSCLC

Patients who progressed on PD-1/PD-L1 inhibitors in Study 303

Trial phase

Phase 2

Study of plinabulin/docetaxel plus pembrolizumab in metastatic NSCLC

ASCO 2026 dates

May 29–June 2, 2026

American Society of Clinical Oncology Annual Meeting schedule

Poster date

May 31, 2026

Scheduled presentation date for Study 303 poster

Presentation time

9:00 a.m.–12:00 p.m. CDT

Time window for the ASCO poster session

Abstract number

8567

ASCO 2026 abstract identifier for the Study 303 poster

Poster board

357

Poster board number assigned at ASCO 2026

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Q1 2026 earnings

   24h Move

   +4.3%

   Quarterly results and pipeline update with modest operating expenses and cash balance.

2. Apr 22

   AACR preclinical data

   24h Move

   -6.9%

   Compelling plinabulin plus ADC preclinical efficacy and safety data at AACR 2026.

3. Mar 30

   AACR poster notice

   24h Move

   +1.3%

   Announcement of AACR 2026 poster on plinabulin–ADC antitumor efficacy.

4. Mar 25

   10-K annual filing

   24h Move

   -4.2%

   Filing of 2025 Form 10-K with audited financial statements and disclosures.

5. Mar 25

   2025 results

   24h Move

   +3.7%

   Year-end results highlighting Phase 3 success for plinabulin and SEED progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2, plinabulin, docetaxel, pembrolizumab, +3 more

7 terms

phase 2 medical

"Title: A Phase 2 Study of Plinabulin (Plin)/Docetaxel..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

plinabulin medical

"A Phase 2 Study of Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab..."

Plinabulin is an experimental small-molecule drug being developed for cancer care that works both by disrupting blood supply to tumors and by stimulating the body’s immune and blood-forming responses; it is also studied for preventing dangerous drops in white blood cells after chemotherapy. Investors pay attention because positive trial results or regulatory approval could create a multi-use treatment with sales potential and reduce chemotherapy complications, similar to a tool that both weakens tumors and protects patients during treatment.

docetaxel medical

"Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab (Pemb) in Metastatic NSCLC..."

A chemotherapy medicine that works by stopping cancer cells from dividing and growing, often used to treat several solid tumors. Investors care because its sales, patent status, approval or label changes, and trial results can significantly affect drugmakers’ revenue and stock value—similar to how a single bestselling product can move a company’s fortunes when customer demand or regulations change.

pembrolizumab medical

"Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab (Pemb) in Metastatic NSCLC..."

A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.

metastatic nsclc medical

"plus Pembrolizumab (Pemb) in Metastatic NSCLC (mNSCLC) After Acquired Resistance..."

Metastatic NSCLC is non-small cell lung cancer that has spread beyond the lungs to other organs; 'non-small cell' describes the most common group of lung cancers while 'metastatic' means the disease is advanced and no longer confined to its original site. It matters to investors because spread disease creates urgent demand for new therapies, longer and riskier clinical programs, larger potential markets for effective drugs, and greater regulatory and pricing pressure—like a small fire that has jumped rooms and requires more complex firefighting.

pd-1/pd-l1 inhibitors medical

"patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors..."

PD-1/PD-L1 inhibitors are drugs that block a molecular “brake” used by some tumors to hide from the immune system: PD-1 is a protein on immune cells and PD-L1 is its partner on cancer cells, and blocking their interaction lets immune cells recognize and attack tumors. Investors care because these therapies can transform cancer treatment, drive significant sales if approved, and their clinical trial results, safety profile and regulatory decisions strongly affect company valuations.

immunophenotyping medical

"Efficacy and Immunophenotyping"

Immunophenotyping is a lab method that identifies and counts different types of immune cells by detecting unique proteins on their surfaces, like reading name tags on cells. For investors, it matters because it helps developers show which patients are likely to benefit, track whether a therapy is hitting its target, and spot safety issues early—information that can reduce clinical trial risk and guide commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL.

Presentation details are as follows:

• Title: A Phase 2 Study of Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab (Pemb) in Metastatic NSCLC (mNSCLC) After Acquired Resistance (AR) to Anti-PD-1/L1 Alone or in Chemotherapy Combination: Efficacy and Immunophenotyping
• Presenter/Authors: Yan Xu, Minjiang Chen, Xiaoxing Gao, Huiyu Huang, Yue Chang, Xiao-Yian Liu, Wei Zhong, Jing Zhao, RuiLi Pan, Taisheng Li, Mengzhao Wang
• Presentation Time: Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT
• Location: McCormick Place, Chicago, IL
• Session: Lung Cancer – Non-Small Cell Metastatic
• Abstract Number: 8567
• Poster Board Number: 357
  

About BeyondSpring

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Learn more at beyondspringpharma.com.

About Study 303

Study 303 is an open-label, single-arm Phase 2 study of plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator, with support from MSD. The study enrolled 47 patients. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes pembrolizumab 200 mg IV every three weeks (Q3W) on Day 1, docetaxel 75 mg/m² IV Q3W on Day 1, and plinabulin 30 mg/m² IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The study is registered on ClinicalTrials.gov under NCT05599789.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause BeyondSpring’s actual results to differ materially from those stated or implied. BeyondSpring undertakes no obligation to update forward-looking statements.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is BeyondSpring (NASDAQ:BYSI) presenting at the 2026 ASCO Annual Meeting?

BeyondSpring is supporting a poster on Study 303, a Phase 2 trial of plinabulin, docetaxel and pembrolizumab in metastatic NSCLC after acquired resistance to anti-PD-1/L1 therapy.

When is BeyondSpring's Study 303 poster session at ASCO 2026?

The Study 303 poster is scheduled for Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT. It will be presented during the Lung Cancer – Non-Small Cell Metastatic session at McCormick Place.

Where will BeyondSpring's ASCO 2026 poster on plinabulin for NSCLC be presented?

The poster will be presented at McCormick Place in Chicago, IL, during the Lung Cancer – Non-Small Cell Metastatic session. According to the company, it is listed as Abstract 8567, Poster Board 357.

What does BeyondSpring's Phase 2 Study 303 in metastatic NSCLC evaluate?

Study 303 evaluates plinabulin/docetaxel plus pembrolizumab in metastatic NSCLC patients who developed acquired resistance to anti-PD-1/L1 alone or in chemotherapy combinations, focusing on efficacy and immunophenotyping outcomes.

Who are the presenters and authors for BeyondSpring's Study 303 poster at ASCO 2026?

The poster lists presenters and authors including Yan Xu, Minjiang Chen, Xiaoxing Gao, Huiyu Huang, Yue Chang, Xiao-Yian Liu, Wei Zhong, Jing Zhao, RuiLi Pan, Taisheng Li, and Mengzhao Wang, reflecting the investigator-initiated nature of Study 303.

Is Merck involved in BeyondSpring's Study 303 presented at ASCO 2026?

Study 303 is described as an investigator-initiated trial supported by Merck (MSD outside the United States and Canada) and BeyondSpring, examining a combination regimen in second- and third-line metastatic NSCLC.